Myopia and Pediatric Myopia Progression: Market View, Current and Future Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3495
Buy Report Download FREE Resources

Published: February 06, 2026 Report Code: GDHC021MV-ST

Select Item

Myopia and pediatric myopia progression market analysis: explore epidemiology, pipeline, clinical trials and competitive landscape. Identify opportunities and support strategy with GlobalData insights.

Understand the Future of the Myopia Therapeutics Market

Myopia and pediatric myopia progression are becoming increasingly important areas within ophthalmology. This report helps you understand how the competitive landscape is evolving across treatments, pipeline assets and clinical activity.

You will gain insight into disease prevalence, treatment approaches and pipeline development. Moreover, the report highlights how innovation is shaping the future of therapeutics in this space.

As a result, you can better assess where opportunities may emerge across the market.

Report Value Proposition – Why This Matters for You

This report goes beyond describing the market. It helps you interpret what the data means for your strategy, investments and competitive positioning.

You can use it to:

  • Identify opportunities across the myopia and pediatric myopia progression pipeline
  • Evaluate competitive positioning and company strategies
  • Understand clinical trial activity and development momentum
  • Support licensing, partnership and investment decisions
  • Benchmark against global leaders and emerging players

In addition, the analysis is built on GlobalData’s Pharma Intelligence Center and analyst expertise. It is trusted by Fortune 500 companies and leading governments worldwide.

Key Insights in Myopia Market and Pipeline Trends

China is anticipated to have the highest number of total prevalent adult myopia cases in both 2024 and 2029, representing a significant share of global cases.

Currently, there are no FDA-approved drugs for myopia and pediatric myopia progression. Atropine sulfate remains the primary established treatment used to slow axial eye growth and manage progression.

The pipeline includes 28 molecules, with three assets in pre-registration, nine in Phase III and seven in Phase II. This reflects a growing focus on therapeutic development in this space.

Clinical activity remains strong, with 286 trials conducted over the past decade. The highest number of studies were initiated in 2021 (38 trials), followed by 2023 (37 trials).

Deal activity is also evolving, with one merger and acquisition and seven strategic alliances completed over the past 34 months. In addition, the market may see an influx of new drugs, supported by late-stage pipeline developments.
Ammonia –Europe and India Attract Major Trade Flows

Scope

What You Will Learn

The report provides a comprehensive view of the myopia and pediatric myopia progression market, including:

  • Disease overview, epidemiology and treatment landscape

  • Marketed products and competitive assessment

  • Pipeline analysis by development stage, mechanism and molecule type

  • Clinical trials analysis across phases, geographies and sponsors

  • Deals landscape including mergers, acquisitions and alliances

  • Pricing, reimbursement and commercial insights

In addition, the report includes product profiles, forecasts and success rate analysis to support decision-making.

Target Buyers for This Report

This report is designed for decision-makers who need clear, actionable insight:

  • Pharmaceutical and biotech executives

  • R&D and clinical development teams

  • Business development and licensing professionals

  • Investors and private equity firms

  • Market intelligence and competitive strategy teams

If you are responsible for growth, pipeline strategy or investment, this report can support your decisions.

How Companies Use This Report

Organizations across the healthcare and pharmaceutical ecosystem can apply this report in practical ways:

  • Pharmaceutical and biotech companies
    Use it to evaluate pipeline assets, identify licensing opportunities and track competitor activity

  • Diagnostics and ophthalmology-focused companies
    Align product and research strategies with emerging treatment approaches

  • Investors and private equity firms
    Assess pipeline strength, deal activity and future growth potential

  • Strategy and business development teams
    Support partnership decisions and identify high-potential assets

As a result, you can move from data to more confident strategic action.

Reasons to Buy

Benchmark Against Global Leaders and Emerging Players

Understanding how companies are positioned across pipeline, trials and deals is critical. Therefore, this report provides a structured view of competitive dynamics and market activity.

You can benchmark pipeline strength, clinical progress and strategic activity across key players. This may help you refine your own positioning and identify partnership opportunities.

Built on Trusted Data and Expert Analysis

This report is backed by GlobalData’s proprietary research and analyst expertise.

  • Built on GlobalData’s Pharma Intelligence Center

  • Trusted by Fortune 500 companies and government institutions

  • Developed by analysts with deep healthcare expertise

Therefore, you can rely on the insights to support high-impact decisions.

Act Now to Stay Ahead in Myopia Therapeutics

The myopia therapeutics landscape is evolving, with increasing pipeline activity and clinical momentum. However, competition and innovation are accelerating.

This report helps you understand where the market is moving and how key players are positioning themselves.

Therefore, if you are evaluating opportunities in myopia and pediatric myopia progression, now is the time to act.

Table of Contents

Table of Contents (PowerPoint Deck)

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

4.2 Overview by Mechanism of Action

4.3 Overview by Molecule Type

4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

5.1 Annual Cost of Therapy

5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

6.1 Mid-to-late-stage Pipeline Drugs

6.2 Overview by Development Stage

6.3 Overview by Mechanism of Action

6.4 Overview by Molecule Type

6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)

6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

7.1 Historical Overview

7.2 Overview by Phase

7.3 Overview by Status

7.4 Overview by Phase for Ongoing and Planned Trials

7.5 Trials with Virtual Components

7.6 Overview of Trials by Geography

7.7 Single-Country and Multinational Trials by Region

7.8 Top 20 Sponsors with Breakdown by Phase

7.9 Top 20 Sponsors with Breakdown by Status

7.10 Overview by Endpoint Status

7.11 Overview by Race and Ethnicity

7.12 Enrollment Data

7.13 Top 20 countries for Trial Sites

7.14 Top 20 Sites Globally

7.15 Feasibility Analysis – Geographic Overview

7.16 Feasibility Analysis – Benchmark Models

8 Deals Landscape

8.1 Mergers, Acquisitions, and Strategic Alliances by Region

8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

11.1 Methodology

11.2 Methodology – Sales Forecast

11.3 Methodology – Pricing and Reimbursement

11.4 Methodology – PTSR and LoA Analysis

11.5 About the Authors

11.6 Contact Us

11.7 Disclaimer

Myopia and Pediatric Myopia Progression: Market View, Current and Future Competitive Landscape standard reports
Currency USD
$3,495

Can be used by individual purchaser only

Most Popular
$6,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Myopia and Pediatric Myopia Progression: Market View, Current and Future Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Myopia reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Pharmaceuticals
New
Overweight and Obesity: Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Myopia and Pediatric Myopia Progression: Market View, Current and Future Competitive Landscape in real time.

  • Access a live Myopia and Pediatric Myopia Progression: Market View, Current and Future Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more